Geron Corp.
GERN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$622.15M
Close$
$-0.03
103.6% downside
Current Fair Value
103.6% downsideOvervalued by 103.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $622.15 Million |
|---|---|
| Enterprise Value | $551.08 Million |
| Earnings per Share | $-0.13 |
| Beta | 0.61 |
| Outstanding Shares | 672,293,000 |
Return
| Return on Equity | -22.11% |
|---|---|
| Return on Assets | -9.51% |
| Return on Invested Capital | -3.84% |
Valuation & Multiples
| P/E Ratio | -13.79 |
|---|---|
| PEG | 12.85 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.53 |
| Enterprise Value to EBIT | -31.69 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS
$0.00
Est. -$0.01Revenue
$60.19 M
Est. $60.36 MNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$65.50 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.12, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.1191▼ 167.82% |
|---|---|
| Total Calls | 346,900▼ 41.09% |
| Total Puts | 41,300▼ 96.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.67%▼ 34.04% |
|---|---|
| Total Invested | $310.54M▼ 49.58% |
| Investors Holding | 160▼ 108.00% |
About Geron Corp.
258 employees
CEO: John Scarlett
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients...